Meet our speaker - Grzegorz Rychwalski

Grzegorz Rychwalski

Grzegorz Rychwalski

PZPPF

Grzegorz Rychwalski

PZPPF

BIO

Vice President of the Management Board
Vice-president of the Polish Association of Pharmaceutical Industry Employers associating the largest domestic pharmaceutical companies, which guarantee Poland's drug safety and the country's economic development. He is an expert in the pharmaceutical sector and European law regulating the production of medicines in the EU.

Previously, he worked, among others as the Head of the Department of Drug Policy and Pharmacy of the Ministry of Health. He was also the attaché for medicinal products and medical devices at the Permanent Representation of the Republic of Poland to the EU in Brussels and the deputy chairman of the Working Group for Pharmaceuticals and Medical Devices of the European Council. He also gained corporate experience as a strategy manager at INFARMA, as well as a governmental affairs & policy manager at Janssen Polska.

On behalf of PZPPF, he monitors the work of the European Commission and the European Parliament, conducts information activities on the role and importance of the domestic pharmaceutical industry. A great success at the EU forum was the presentation in May of last year. by the European Commission a draft regulation introducing the possibility of producing equivalents of SPC-protected drugs for export outside the EU. A continuation of these activities was the battle to introduce changes to the draft regulation that would be beneficial for domestic drug producers. Thanks to them, domestic pharmaceutical companies will be able to compete on an equal footing with companies from the USA, China and South America on the markets of third countries.

The public activity of Grzegorz Rychwalski, vice-president of PZPPF, also focuses on education on equivalent biological medicines, thanks to which Polish patients can have wider access to modern biological therapies. He is responsible for dialogue with patients, clinicians, the Patient Ombudsman and regulators of this market. Together with the linguist prof. Jerzy Bralczyk promotes the use of the name "biological equivalent" drugs instead of "biosimilar".